Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Go back to Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis| CELLDEX THERAPEUTICS, Inc. (NASDAQ: CLDX) | Delayed: 35.42 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $35.42 | 52 Week High | $18.62 | |||
| Open | $35.42 | 52 Week Low | $2.85 | |||
| Day High | $35.42 | P/E | N/A | |||
| Day Low | $35.42 | EPS | $-1.02 | |||
| Volume | 377 | |||||
